Hints and tips:
...“The legal case against AbbVie concerns the fundamental question to what extent pharmaceutical companies like AbbVie are free to set and maintain the prices of the drugs they offer,” the PAF said....
...Yet AbbVie’s monopoly barely wavered....
...AbbVie’s Humira, used for a range of autoimmune diseases, became the world’s best-selling drug but has recently had its market exclusivity expire....
...Last year a US appeals court ruled that AbbVie’s use of a patent thicket did not unlawfully block competition....
...US drugmakers AbbVie and Eli Lilly have become the first pharmaceutical groups to pull out of a pricing agreement with the UK government in protest at a sharp rise in clawback payments....
...But the one that made $200bn for AbbVie cannot be right. john.gapper@ft.com...
...In March Pfizer swooped on Seagen, announcing a deal for a total enterprise value of $43bn, which was the largest pharmaceutical transaction announced since AbbVie agreed to buy Allergan in 2019....
...The deal is the largest pharmaceutical transaction since AbbVie agreed to buy Allergan for $63bn in 2019 and signals a rebound in mergers and acquisitions following a dip in activity last year, according...
...Humira, the world’s best-selling drug, which has amassed $200bn in global sales for AbbVie, faced competition in Europe in 2018....
...Of these, seven were classic defensives (Merck, AbbVie, Pepsi, Raytheon, UnitedHealth, Walmart, and Coca-Cola). Unhedged has been writing about this pattern a lot for almost a year and a half now....
...Tim Walbert, Horizon’s chief executive, suffers from an autoimmune condition himself, and previously led the global development of Abbvie’s blockbuster Humira....
...AbbVie, which manufactures the blockbuster rheumatoid arthritis drug Humira, booked 99 per cent of 2020 sales in foreign subsidiaries even though three quarters of sales were made in the US, according to...
...It exited its position in generic drugs maker Teva and sold more than 70 per cent of its remaining shares in AbbVie and Bristol-Myers Squibb....
...Several other large US pharma groups, including Eli Lilly, AbbVie and Amgen have clinched similar agreements over the past two years as western drugmakers increasingly seek to license high-potential therapies...
...Pfizer, AbbVie and Bristol-Myers Squibb all have blockbuster drugs due to lose exclusivity soon and have recently sealed multibillion-dollar deals....
...Berkshire reduced its stakes in drugmakers including Merck, Bristol-Myers Squibb and AbbVie in the first quarter, cut more than half of its holding in oil major Chevron, and sold the entirety of its positions...
...It increased its stakes in AbbVie, Bristol-Myers Squibb and Merck, but sold out of Pfizer....
...Berkshire’s new stake accounted for 1.3 per cent of Bristol-Myers shares outstanding, 1.2 per cent of AbbVie, 0.9 per cent of Merck and less than 0.1 per cent of Pfizer....
...AbbVie’s mega-deal had been called into question by several investors in February as they feared that regulators would block the Botox maker’s takeover....
...The acquisition is the biggest transaction in pharmaceuticals since 2019, when AbbVie acquired Allergan for $63bn, and the largest deal to target a US company in any sector this year....
...“AbbVie did the right thing,” said Ms ‘t Hoen. “But it foremost shows the power of the measure....
...AbbVie significantly raised its guidance for 2020, sending shares up 5 per cent to more than $91 in mid-morning trading in New York....
...Despite the hefty borrowing, AbbVie is expected to cling on to its investment-grade bond rating....
...(FT) News round-up US regulator clears AbbVie’s $63bn deal for Allergan (FT) KKR posts $4.2bn net loss as investment portfolio hit (FT) Goldman Sachs in talks to buy Invesco holdings (Sky News) Warburg...
...AbbVie borrowed $30bn from investors this month to fund its takeover of rival pharmaceutical company Allergan....
International Edition